New Agents in Chronic Myelogenous Leukemia

2003 ◽  
Vol 1 (4) ◽  
pp. 501-512
Author(s):  
Jorge Cortes ◽  
Francis Giles
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Mechanisms Of Action ◽  
Myelogenous Leukemia ◽  
New Agents ◽  
Complete Eradication ◽  
Intracellular Pathways

Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.

scholarly journals Personalized Immunotherapy Treatment Strategies for a Dynamical System of Chronic Myelogenous Leukemia

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2030
Author(s):  
Paul A. Valle ◽  
Luis N. Coria ◽  
Corina Plata
Keyword(s):  
Dynamical System ◽  
Cancer Cells ◽  
Chronic Myelogenous Leukemia ◽  
Sufficient Conditions ◽  
Treatment Strategies ◽  
Myelogenous Leukemia ◽  
Invariant Sets ◽  
Cellular Immunotherapy ◽  
Complete Eradication ◽  
Treatment Parameter

This paper is devoted to exploring personalized applications of cellular immunotherapy as a control strategy for the treatment of chronic myelogenous leukemia described by a dynamical system of three first-order ordinary differential equations. The latter was achieved by applying both the Localization of Compact Invariant Sets and Lyapunov’s stability theory. Combination of these two approaches allows us to establish sufficient conditions on the immunotherapy treatment parameter to ensure the complete eradication of the leukemia cancer cells. These conditions are given in terms of the system parameters and by performing several in silico experimentations, we formulated a protocol for the therapy application that completely eradicates the leukemia cancer cells population for different initial tumour concentrations. The formulated protocol does not dangerously increase the effector T cells population. Further, complete eradication is considered when solutions go below a finite critical value below which cancer cells cannot longer persist; i.e., one cancer cell. Numerical simulations are consistent with our analytical results.

scholarly journals New Agents in the Treatment of Chronic Myelogenous Leukemia

2009 ◽  
Vol 7 (9) ◽  
pp. 1028-1037 ◽  
Author(s):  
Javier Pinilla-Ibarz ◽  
Alfonso Quintás-Cardama
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
New Agents

Expression of a Multidrug Resistance Gene in Blast Crisis of Chronic Myelogenous Leukemia

1989 ◽  
Vol 1 (2) ◽  
pp. 141-144 ◽  
Author(s):  
Robert Pirker ◽  
Lori J. Goldstein ◽  
Heinz Ludwig ◽  
Werner Linkesch ◽  
Christina Lechner ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Resistance Gene ◽  
Chronic Myelogenous Leukemia ◽  
Blast Crisis ◽  
Myelogenous Leukemia ◽  
Multidrug Resistance Gene
Sign in / Sign up

Export Citation Format

Share Document